Literature DB >> 12525283

Treatment options for brain metastases in patients with non-small cell lung cancer.

Sadaf Taimur1, Martin J Edelman.   

Abstract

Brain metastases are a common complication for patients with non-small cell lung cancer and a significant cause of morbidity and mortality. In the past, treatment of brain metastases and lung cancer focused on symptom palliation with whole brain radiotherapy (WBRT) and steroids because of the grim outlook for patients. However, recent advances in technology and surgical techniques have created more options for the management of brain metastases, which include surgery, irradiation, stereotactic radiosurgery, and chemotherapy. These aggressive approaches have resulted in an improvement of neurologic outcomes and survival rates of patients with non-small cell lung cancer. Central nervous system (CNS) metastases can be divided into three groups: solitary CNS metastases with controlled or controllable primary disease, oligometastatic disease (fewer than three metastases), and multiple metastases. For patients with solitary CNS metastases, long-term survival is possible. A radical treatment approach involving surgical resection or radiosurgery, followed by WBRT, is recommended. For patients with oligometastatic disease, surgical resection or radiosurgery is considered in selected cases and WBRT is indicated. For patients with multiple metastases, WBRT is recommended. For patients with oligometastatic disease and patients with multiple metastases, recent evidence indicates that systemically effective chemotherapy may produce responses and can be instituted safely before radiotherapy. The treatment timing of chemotherapy and radiotherapy should be individualized.

Entities:  

Mesh:

Year:  2003        PMID: 12525283     DOI: 10.1007/s11864-003-0035-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  33 in total

1.  Comparison of three treatment options for single brain metastasis from lung cancer.

Authors:  B Li; J Yu; M Suntharalingam; A S Kennedy; P P Amin; Z Chen; R Yin; S Guo; T Han; Y Wang; N Yu; G Song; L Wang
Journal:  Int J Cancer       Date:  2000-02-20       Impact factor: 7.396

2.  Radiosurgery for brain metastases from primary lung carcinoma.

Authors:  R Hoffman; P K Sneed; M W McDermott; S Chang; K R Lamborn; E Park; W M Wara; D A Larson
Journal:  Cancer J       Date:  2001 Mar-Apr       Impact factor: 3.360

3.  Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1.

Authors:  G Robinet; P Thomas; J L Breton; H Léna; S Gouva; G Dabouis; J Bennouna; P J Souquet; P Balmes; L Thiberville; P Fournel; E Quoix; R Riou; P Rebattu; M Pérol; D Paillotin; F Mornex
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

4.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.

Authors:  B Borgelt; R Gelber; S Kramer; L W Brady; C H Chang; L W Davis; C A Perez; F R Hendrickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-01       Impact factor: 7.038

Review 5.  Temozolomide for treating brain metastases.

Authors:  L E Abrey; C Christodoulou
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

6.  Management of central nervous system metastases.

Authors:  J B Posner
Journal:  Semin Oncol       Date:  1977-03       Impact factor: 4.929

7.  Factors influencing survival after gamma knife radiosurgery for patients with single and multiple brain metastases.

Authors:  H K Shu; P K Sneed; C Y Shiau; M W McDermott; K R Lamborn; E Park; M Ho; P L Petti; V Smith; L J Verhey; W M Wara; P H Gutin; D A Larson
Journal:  Cancer J Sci Am       Date:  1996 Nov-Dec

Review 8.  Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control.

Authors:  C Y Shiau; P K Sneed; H K Shu; K R Lamborn; M W McDermott; S Chang; P Nowak; P L Petti; V Smith; L J Verhey; M Ho; E Park; W M Wara; P H Gutin; D A Larson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

9.  Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.

Authors:  R Komaki; C B Scott; W T Sause; D H Johnson; S G Taylor; J S Lee; B Emami; R W Byhardt; W J Curran; A R Dar; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

10.  Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer.

Authors:  V Minotti; L Crinò; M L Meacci; E Corgna; S Darwish; M A Palladino; M Betti; M Tonato
Journal:  Lung Cancer       Date:  1998-05       Impact factor: 5.705

View more
  2 in total

1.  Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.

Authors:  Jane W Marsh; Maryann Donovan; Dennis R Burholt; Lisa D George; Paul L Kornblith
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

2.  Trans-differentiation of neural stem cells: a therapeutic mechanism against the radiation induced brain damage.

Authors:  Kyeung Min Joo; Juyoun Jin; Bong Gu Kang; Se Jeong Lee; Kang Ho Kim; Heekyoung Yang; Young-Ae Lee; Yu Jin Cho; Yong-Seok Im; Dong-Sup Lee; Do-Hoon Lim; Dong Hyun Kim; Hong-Duck Um; Sang-Hun Lee; Jung-Ii Lee; Do-Hyun Nam
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.